BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Colorectal cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for colorectal cancer: 576 (356 sponsors; 89 newly posted in the last 180 days, 33 stopped in the last 180 days; 42 new-entrant sponsors). Momentum score 9.7, rank 72 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 6, Phase 1 182, Phase 2 223, Phase 3 56, Phase 4 3, N/A 106.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Exelixis EXEL6P3 3, P1 321
GlaxoSmithKline11P2 7, P1 2, P3 221
Pfizer PFE11P1 5, NA 1, P3 2, P4 1, P2 231
Bristol-Myers Squibb BMY8P1 2, P2 4, P3 210
Akeso6P2 4, P3 203
Qilu Pharmaceutical Co., Ltd.5P3 2, P1 310
Genmab GMAB4P3 2, P2 220
Janssen Research & Development, LLC4P2 1, P3 2, P1 101
Merck Sharp & Dohme LLC MRK4P3 2, P2 201
Shanghai JMT-Bio Inc.3P2 1, P3 200
Suzhou Suncadia Biopharmaceuticals Co., Ltd.3P3 2, P2 110
Natureceuticals Sdn Bhd new entrant2P3 221
AbbVie ABBV10P1 5, P2 4, P3 111
Sichuan Baili Pharmaceutical Co., Ltd.6P1 4, P3 1, P2 112
Incyte Corporation INCY5P3 1, P2 2, P1 212
Seagen, a wholly owned subsidiary of Pfizer5P2 3, P3 1, P1 100
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.4P3 1, P2 2, P1 110
Genfleet Therapeutics (Shanghai) Inc.4P2 3, P3 120
Shanghai Henlius Biotech4P2 2, P1 1, P3 101
Jiangsu Famous Medical Technology Co., Ltd.3P3 1, NA 211
Amgen AMGN2P1 1, P3 100
EMD Serono Research & Development Institute, Inc.2P1 1, P3 100
Immunophotonics, Inc.2P3 1, P2 100
Innovent Biologics (Suzhou) Co. Ltd.2P3 1, P2 110
Jiangsu HengRui Medicine Co., Ltd.2P3 1, P2 110

New-entrant sponsors: Natureceuticals Sdn Bhd.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2BeyondBio Inc.NCT05093907 A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal CancerMetastatic Colorectal Cancerrecruiting27
2026-12 est.P1/P2Rottapharm BiotechNCT05205330 Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI CancersRefractory Metastatic Colorectal Cancer; Solid Tumor; Metastatic Microsatellite-stable Colorectal Caactive not recruiting107
2026-12 est.P1/P2A2 Biotherapeutics Inc.NCT05736731 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionSolid Tumor, Adult; Solid Tumor; Pancreatic Cancer; Pancreatic Neoplasms; Pancreas Cancer; Non Smallactive not recruiting160
2026-12 est.P1/P2TiumBio Co., Ltd.NCT05784688 Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsSolid Tumor; Biliary Tract Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancerrecruiting140
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06008054 A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, CoEsophageal Cancer; Gastric Cancer; Colorectal Cancerrecruiting376
2026-12 est.P2AbbVie ABBVNCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable MetUnresectable Metastatic Colorectal Canceractive not recruiting280
2026-12 est.P1/P2858 Therapeutics, Inc.NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesAdvanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarrecruiting120
2026-12 est.P2Delcath Systems Inc. DCTHNCT06607458 Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or ApprRefractory Metastatic Colorectal Cancerrecruiting90
2026-12 est.P2Shandong New Time Pharmaceutical Co., LTDNCT06722950 Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral NeuropathyColorectal Adenomanot yet recruiting120
2026-12 est.P1/P2AkesoNCT06943820 AK129 Combination Therapy for Advanced Solid TumorsNon-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal recruiting230
2026-12 est.P1/P2One-carbon Therapeutics ABNCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid TumorsSolid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung recruiting43
2026-12 est.P2Shenyang Sunshine Pharmaceutical Co., LTD.NCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal CancersGastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Ducnot yet recruiting300
2026-12-15 est.P1/P2PMV Pharmaceuticals, Inc PMVPNCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Crecruiting300
2026-12-24 est.P3Shanghai Kechow Pharma, Inc.NCT06008119 Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal CancerColorectal Cancer Metastaticrecruiting165
2026-12-30 est.P1/P2Astellas Pharma Global Development, Inc.NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metastaactive not recruiting240
2026-12-30 est.P2Shanghai Henlius BiotechNCT07106892 Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal CancerColorectal Cancer (CRC)recruiting60
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P1/P2Chimeric TherapeuticsNCT06055439 A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell TherapyNeuroendocrine Tumors; Colorectal Cancer; Gastric Canceractive not recruiting135
2026-12-31 est.P2Shanghai Pharmaceuticals Holding Co., LtdNCT06434597 A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.Biliary Tract or Colorectal Cancer With Her2-positive/Mutatedrecruiting60
2026-12-31 est.P2Jazz Pharmaceuticals JAZZNCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsBreast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endomerecruiting200
2027-01-01 est.P2Tasly Biopharmaceuticals Co., Ltd.NCT06838546 A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal CancerAdvanced Colorectal Cancernot yet recruiting80
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-01-13 est.P3AkesoNCT06951503 AK112 and Chemotherapy in First-line Metastatic Colorectal CancerColorectal Adenocarcinomarecruiting560
2027-01-25 est.P1/P2Novartis Pharmaceuticals NVSNCT04699188 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lungactive not recruiting344
2027-01-29 est.P1/P2IDEAYA Biosciences IDYANCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsMetastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumorsrecruiting336
2027-01-31 est.P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07202364 A Study of YL202 in Patients With Advanced Solid TumorsNon Small Cell Lung Cancer; Colorectal Cancer; Cervical Cancer; Locally Advanced or Metastatic Solidrecruiting100
2027-02 est.P1/P2Lumicell, Inc.NCT02584244 Feasibility of the LUM Imaging System for Detection of Gastrointestinal CancersColorectal Cancer; Pancreatic Cancer; Esophageal Cancer; Gastric Canceractive not recruiting66

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2027-02-01 (month)PDUFA date (company-disclosed)pendingANAPTYSBIO, INC ANABPDUFA February 2027 - ANAPTYSBIO, INC

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P1/P2Bexion Pharmaceuticals, Inc.NCT05322590 BXQ-350 in Newly Diagnosed Metastatic Colorectal CarcinomaMetastatic Colorectal Carcinoma; Neuropathyactive not recruiting195
2026-11 est.P2BioNTech SE BNTXNCT04486378 A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage IColorectal Cancer Stage II; Colorectal Cancer Stage IIIactive not recruiting327
2026-10-31 est.P3Natureceuticals Sdn BhdNCT07669454 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule inFatigue Related to Cancer Treatment; Colon Cancerrecruiting250
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-01P1/P2Merus B.V.NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationNon-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and terminated194
2026-10 est.P2Vyriad, Inc.NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsMelanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Canceractive not recruiting87
2026-09-30 est.P2Kahr Bio Australia Pty LtdNCT07235293 A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.Colorectal Cancerrecruiting90
2026-09-28P1/P2Novartis Pharmaceuticals NVSNCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Sterminated74
2026-08 est.P2Tasly Biopharmaceuticals Co., Ltd.NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsRecurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervicnot yet recruiting120
2026-07 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07044908 TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal CancerRAS/BRAF Wild Type Colorectal Cancerrecruiting72
2026-06-30 est.P3Taizhou Hanzhong biomedical co. LTDNCT05652894 A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal CancerMetastatic Colorectal Canceractive not recruiting190
2026-06-22 est.P1/P2GlaxoSmithKlineNCT06710847 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in ParticNeoplasms, Colorectal; Solid Tumor; Colon Cancer; Rectal Cancer; Endometrial Canceractive not recruiting14
2026-06-19P2Pfizer PFENCT05217446 A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic ColorectaMetastatic Colorectal Canceractive not recruiting108
2026-06-16P3Exelixis EXELNCT05425940 Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerColorectal Canceractive not recruiting901
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-06 est.P2Actuate Therapeutics Inc. ACTUNCT03678883 9-ING-41 in Patients With Advanced CancersCancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractoryactive not recruiting350

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "colorectal cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.